<DOC>
	<DOCNO>NCT02751879</DOCNO>
	<brief_summary>This non-interventional , multi-country , multi-site study base exist data medical record patient treat Gi ( l ) otrif® part routine treatment accord approve label . Data real-world help understand dose modification do similar LUX-Lung 3 trial outcome safety effectiveness trial setting . Furthermore , data modify start dos , underlie reason effect safety outcome need .</brief_summary>
	<brief_title>Real World Data Gi ( l ) Otrif® Dose Adjustment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Age = 18 year 2 . Patients EGFR mutation ( common mutation ) , TKInaïve advance NSCLC , treat Gi ( l ) otrif® firstline treatment NSCLC within approve label 3 . Signed date write informed consent per regulation . ( Exemption write informed consent retrospective observational study country per local regulation legal requirement . ) Exclusion criterion : 1 . Any contraindication Gi ( l ) otrif® specify label . 2 . Patients uncommon mutation exclude uncommon mutation within label participate country ( e.g . USA ) . 3 . Patients still treatment Gi ( l ) otrif® exclude unless treatment period &gt; = 6 month . 4 . Patients treat Gi ( l ) otrif® within interventional trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>